Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02003222 · OUTCOME

OS Among MRD Negative Patients Who Proceed to Allogeneic Transplant on Study

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years

What was measured

OS was defined as time from allogeneic transplant to death of any cause.

Analysis population: MRD negative patients who proceeded to allogeneic transplant after treatment with blinatumomab plus chemotherapy or chemotherapy alone were included in this analysis.

Groups in this outcome

MRD Negative Patients Receiving Blinatumomab + Chemotherapy and Then Allogeneic Transplant

Patients who proceed to allogeneic blood or marrow transplant after treatment with blinatumomab and chemotherapy.

MRD Negative Patients Receiving Chemotherapy and Then Allogeneic Transplant

Patients who proceed to allogeneic blood or marrow transplant after treatment with chemotherapy. .

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
MRD Negative Patients Receiving Blinatumomab + Chemotherapy and Then Allogeneic Transplant22
MRD Negative Patients Receiving Chemotherapy and Then Allogeneic Transplant22

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
MRD Negative Patients Receiving Blinatumomab + Chemotherapy and Then Allogeneic TransplantNANot reportedNANAMedian OS not reached The 95% confidence intervals were not calculable because an insufficient number of participants reached the event at the final time point for assessment.
MRD Negative Patients Receiving Chemotherapy and Then Allogeneic TransplantNANot reported30.2NAMedian OS not reached The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.17
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    2.11
    estimate Comment
    hazard ratio: blinatumomab + chemotherapy vs. chemotherapy alone
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.41
    param Type
    Hazard Ratio (HR)
    param Value
    0.59
    statistical Method
    Log Rank
Complete source fields
analyses
  1. ci Lower Limit
    0.17
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    2.11
    estimate Comment
    hazard ratio: blinatumomab + chemotherapy vs. chemotherapy alone
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.41
    param Type
    Hazard Ratio (HR)
    param Value
    0.59
    statistical Method
    Log Rank
classes
  1. categories
    1. measurements
      1. comment
        Median OS not reached The 95% confidence intervals were not calculable because an insufficient number of participants reached the event at the final time point for assessment.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
      2. comment
        Median OS not reached The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.
        group Id
        OG001
        lower Limit
        30.2
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    2. group Id
      OG001
      value
      22
    units
    Participants
description
OS was defined as time from allogeneic transplant to death of any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients who proceed to allogeneic blood or marrow transplant after treatment with blinatumomab and chemotherapy.
    id
    OG000
    title
    MRD Negative Patients Receiving Blinatumomab + Chemotherapy and Then Allogeneic Transplant
  2. description
    Patients who proceed to allogeneic blood or marrow transplant after treatment with chemotherapy. .
    id
    OG001
    title
    MRD Negative Patients Receiving Chemotherapy and Then Allogeneic Transplant
param Type
MEDIAN
population Description
MRD negative patients who proceeded to allogeneic transplant after treatment with blinatumomab plus chemotherapy or chemotherapy alone were included in this analysis.
reporting Status
POSTED
time Frame
Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years
title
OS Among MRD Negative Patients Who Proceed to Allogeneic Transplant on Study
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice